HRG and neoplasm: We have previously shown that HRG, either administered as a recombinant protein, overexpressed by tumor cells, or delivered through adenovirus-mediated gene therapy, polarizes monocytes/macrophages to an anti-tumor immune profile, allowing for the recruitment of cytotoxic T cells to the tumor [1,16,24].